Evidence Reviews and White Papers

Documents

Performance evaluation of a rapid multiplex point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 Antigen and Flu A/B

External Publication from BMJ Open: Narrative review of C reactive protein (CRP) point-of-care testing (POCT) and antibacterial use in patients presenting with respiratory tract infections symptoms

LumiraDx SARS-CoV-2 Antibody Test Demonstrates High Sensitivity and Specificity in Point of Care Testing for COVID-19

LumiraDx SARS-CoV-2 Antigen Test Demonstrates High Sensitivity in Point of Care Testing for COVID-19

NHS Scotland Assessment of LumiraDx SARS-CoV-2 Ab Test

Performance evaluation of a rapid point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 antibodies

COVID-19 Asymptomatic Testing with POC LumiraDx SARS-CoV-2 Antigen Test

SARS-CoV-2 Ag Test Superior Analytical Sensitivity – Technical Bulletin

The quantitative LumiraDx D-Dimer Test provides lab-comparable results at the point of care

CTSB enables the next step of normal life to resume: Usage of LumiraDx SARS-CoV-2 Ag Pool Test supports opening strategies for social events in Germany

Performance of a SARS-CoV-2 Antigen Pool Test to aid diagnosis of acute COVID-19 at the point of care

Performance evaluation of the quantitative point-of-care LumiraDx D-Dimer Test

The LumiraDx SARS-CoV-2 Antigen Test demonstrated as more sensitive compared to SD Biosensor Standard Q COVID-19 Rapid Antigen Test in an independent evaluation on behalf of the Swiss Federal Office of Public Health

The LumiraDx SARS-CoV-2 Antigen Test aligns with detection of infectious samples from immunocompetent individuals with none to mild and moderate symptoms

Summary of the Evaluation of 32 rapid tests for detection of IgG antibodies against SARS-CoV-2 (NOKLUS)

Establishing an Anticoagulation “Drive Through” Clinic during the COVID-19 Pandemic using the LumiraDx Platform INR Test

An evaluation of the detection of SARS-CoV-2 antigen in a cohort of symptomatic and asymptomatic patients: Report from the evaluation of SKUP

Performance evaluation of the LumiraDx SARS-CoV-2 Antigen Test to aid diagnosis of acute COVID-19 at the point of care

Evaluation of the Accuracy of the LumiraDx INR Test Using Patients in Receipt of Phenprocoumon Anticoagulation Therapy

Evaluation of the Accuracy of INR values measured by a POCT system in a German Clinic with patients taking Phenprocoumon as VKA Therapy.

Laboratory accuracy assessment of a novel INR Point of Care Test compared with laboratory reference methods used across four independent clinical sites.

Evaluation of the Accuracy of INR values measured by LumiraDx in patients taking Phenprocoumon.

Sensitivity of LumiraDx INR Testing to Interference from Antiphospholipid Antibodies (aPL)

The LumiraDx Platform INR Test: Performance and ease of use in an anticoagulation clinic setting

LumiraDx INR Test: Laboratory Accuracy Assessment with the ACL Elite and Sysmex Reference Methods

Product Evaluation of the LumiraDx Platform and INR Test at the medical practice Dres. Schreiber, Steinbauer & Dechant

Performance of the LumiraDx Platform INR Test in a point of care setting compared to an established laboratory reference method

Point of care testing in primary care in Europe: Improving pathways and patient outcomes

Point of care testing in the community pharmacy – improving access to care.

BetterHealthExperiencesOutcomes

Supporting healthier lives, for individuals, communities and wider society.

Enabling responsive, personal relationships between patients and care teams.

Controlling and reducing costs to help ease pressure on healthcare budgets.

Be Informed